Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Royer

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Clinical Hematology International|June 1, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in FranceDecaux Olivier, Ronan Garlantezec, Aurore Perrot, et al.
Blood|November 21, 2024
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohortPierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, et al.
Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Blood|January 11, 2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsXavier Leleu, Lionel Karlin, Margaret Macro, et al.
American Journal of Hematology|January 2, 2023
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome studyCharles Dumontet, Delphine Demangel, Perrine Galia, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
The Lancet. Oncology|October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Blood|September 2, 2022
Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort studyStéphanie Guillet, Valentine Loustau, Emmanuelle Boutin, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Clinical Hematology International|June 1, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in FranceDecaux Olivier, Ronan Garlantezec, Aurore Perrot, et al.
Blood|November 21, 2024
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohortPierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, et al.
Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Blood|January 11, 2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsXavier Leleu, Lionel Karlin, Margaret Macro, et al.
American Journal of Hematology|January 2, 2023
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome studyCharles Dumontet, Delphine Demangel, Perrine Galia, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
The Lancet. Oncology|October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Blood|September 2, 2022
Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort studyStéphanie Guillet, Valentine Loustau, Emmanuelle Boutin, et al.
Pageof 11